Detail akcie Angle online

Business Summary: Cellbxhealth PLC, formerly ANGLE plc, is a global precision circulating tumor cell (CTC) intelligence company specializing in innovative circulating tumor cell solutions for use in research, drug development and clinical oncology. The product portfolio comprises the Parsortix platform with associated consumables and assays. Its Parsortix platform harvests CTCs from blood and enables comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows - supporting research, drug development and clinical oncology. Its Parsortix PC1 system is the first FDA cleared medical device for the capture and harvest of intact CTCs from metastatic breast cancer (MBC) patient blood for subsequent, user-validated analysis.Its Parsortix PR1 System is a semi-automated platform for epitope-independent CTC isolation, used in research and clinical trials for multiple cancer types.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Cellbxhealth PLC revenues decreased 23% to L796K. Net loss increased 20% to L9.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Operating costs increase of 14% to L10.1M (expense), finance income decrease of 49% to L96K (income), Finance costs increase of 8% to L151K (expense).